Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812429 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT06812429 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 6 participants.
The verdict
NCT06812429, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
Interventions
- DRUG Dapagliflozin (DAPA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-05-08 |
| Est. Completion | 2025-04-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06812429
The ClinicalTrials.gov registry entry for NCT06812429 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dapagliflozin (DAPA) is the first listed.
NCT06812429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06812429 about?
NCT06812429 is a clinical study titled "Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation". The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
What is the current status of trial NCT06812429?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2024-05-08. Estimated completion is 2025-04-05.
What interventions are being tested in trial NCT06812429?
The interventions under investigation include: Dapagliflozin (DAPA) (DRUG).
Who is sponsoring clinical trial NCT06812429?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.